Literature DB >> 10931365

Grading of diffusely infiltrating astrocytomas by quantitative histopathology, cell proliferation and image cytometric DNA analysis. Comparison of 133 tumours in the context of the WHO 1979 and WHO 1993 grading schemes.

P K Sallinen1, S L Sallinen, P T Helén, I S Rantala, E Rautiainen, H J Helin, H Kalimo, H K Haapasalo.   

Abstract

The aim of the study was to evaluate the applicability of quantitative histopathology as an aid for grading diffusely infiltrating astrocytomas. Primary astrocytomas were analysed for parameters (mean nuclear size, mitosis count, area fraction of endothelial cells and tumour necrosis, area fraction of nuclei, and Ki-67 (MIB-1) labelling index), which are closely related to the World Health Organization (WHO) 1979 and WHO 1993 grading criteria. All estimates correlated with the WHO histopathological grade and patient outcome. According to the receiver-operating characteristics curve, the presence of tumour necrosis and mitosis count (cut-off at 3 mitoses/mm2 of neoplastic tissue) showed the best sensitivity and specificity in separating patients with different survival. The multivariate survival analyses confirmed this result. A decision-tree model was constructed based on these two variables: twig I with less than 3 mitoses/mm2, twig II with equal or more than 3 mitoses/mm2 but no necrosis, and twig III with tumour necrosis. This model was found to be more strongly associated with survival than the WHO 1979 or WHO 1993 grading schemes. Low-malignancy astrocytomas (WHO grade II or twig I tumours) could be further divided into two prognostic categories by the image cytometric DNA analysis. The results put an emphasis on astrocytoma grading on mitosis counts (grade II vs. III) and tumour necrosis (grade III vs. IV). To standardize the sampling for mitosis counting, it is suggested that a parallel Ki-67 immunostaining be used for the identification of the most proliferative areas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931365     DOI: 10.1046/j.1365-2990.2000.00240.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  10 in total

1.  CHEK2 mutations in primary glioblastomas.

Authors:  Satu-Leena Sallinen; Tarja Ikonen; Hannu Haapasalo; Johanna Schleutker
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

2.  CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients.

Authors:  A Salmaggi; M Gelati; B Pollo; C Marras; A Silvani; M R Balestrini; M Eoli; L Fariselli; G Broggi; A Boiardi
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

3.  The boron-neutron capture agent beta-D-5-o-carboranyl-2'-deoxyuridine accumulates preferentially in dividing brain tumor cells.

Authors:  Casey Moore; Brenda I Hernández-Santiago; Selwyn J Hurwitz; Chalet Tan; Chris Wang; Raymond F Schinazi
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

4.  MR imaging correlates of survival in patients with high-grade gliomas.

Authors:  Whitney B Pope; James Sayre; Alla Perlina; J Pablo Villablanca; Paul S Mischel; Timothy F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2005 Nov-Dec       Impact factor: 3.825

5.  Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas.

Authors:  J Haapasalo; A Mennander; P Helen; H Haapasalo; J Isola
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 6.  Prognostic factors for anaplastic astrocytomas.

Authors:  Alessia Compostella; Alicia Tosoni; Valeria Blatt; Enrico Franceschi; Alba A Brandes
Journal:  J Neurooncol       Date:  2006-09-26       Impact factor: 4.130

7.  Role of MIB1 in predicting survival in patients with glioblastomas.

Authors:  Shaye I Moskowitz; Tao Jin; Richard A Prayson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

8.  Identifying the association between contrast enhancement pattern, surgical resection, and prognosis in anaplastic glioma patients.

Authors:  Yinyan Wang; Kai Wang; Jiangfei Wang; Shaowu Li; Jun Ma; Jianping Dai; Tao Jiang
Journal:  Neuroradiology       Date:  2016-01-21       Impact factor: 2.804

9.  Immunohistochemical markers for prognosis of anaplastic astrocytomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

10.  Brain tumor classification using AFM in combination with data mining techniques.

Authors:  Marlene Huml; René Silye; Gerald Zauner; Stephan Hutterer; Kurt Schilcher
Journal:  Biomed Res Int       Date:  2013-08-25       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.